Combination Immunotherapy Approaches in Metastatic Renal Cell Carcinoma with Favorable Risk Scores: A Meta-Analysis of Individual Patient Data - Scorecard - MDSpire

Combination Immunotherapy Approaches in Metastatic Renal Cell Carcinoma with Favorable Risk Scores: A Meta-Analysis of Individual Patient Data

  • By

  • Mattia Alberto Di Civita

  • Daniele Marinelli

  • Valerio Marco Michetti

  • Adele Artemi

  • Andrea Ballario

  • Andrea Torchia

  • Laura Pappalardo

  • Martina Pecoraro

  • Iolanda Speranza

  • Alessandro Sciarra

  • Valeria Panebianco

  • Michela Roberto

  • Daniele Santini

  • January 8, 2026

  • 0 min

Share

Clinical Scorecard: Combination Immunotherapy Approaches in Metastatic Renal Cell Carcinoma with Favorable Risk Scores: A Meta-Analysis of Individual Patient Data

At a Glance

CategoryDetail
Condition
Key MechanismsCombination therapies involving immune-checkpoint inhibitors (ICIs) such as anti-PD-1, anti-PD-L1, and tyrosine kinase inhibitors (TKIs) targeting VEGF.
Target Population
Care Setting

Key Highlights

  • Favorable risk patients show reduced disease progression risk with ICI-TKI combinations but no significant OS improvement over sunitinib in this subgroup.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Assess PFS and OS regularly, including specific metrics such as imaging frequency and clinical evaluations.

      Risks

        Patient & Prescribing Data

        Monotherapy with TKIs remains a viable option for favorable risk patients, but consider potential side effects and patient preferences.

        Clinical Best Practices

        • Incorporate patient risk stratification in treatment decision-making.
        • Regularly evaluate treatment responses and adjust strategies as necessary.
        • Involve a multidisciplinary team in treatment planning.

        References

        Original Source(s)

        Combination Immunotherapy Approaches in Metastatic Renal Cell Carcinoma with Favorable Risk Scores: A Meta-Analysis of Individual Patient Data

        • by Mattia Alberto Di Civita, Daniele Marinelli, Valerio Marco Michetti, Adele Artemi, Andrea Ballario, Andrea Torchia, Laura Pappalardo, Martina Pecoraro, Iolanda Speranza, Alessandro Sciarra, Valeria Panebianco, Michela Roberto, Daniele Santini

        • January 8, 2026

        Related Content

        Endogenous Competition of circ_001024 for miR-145-3p: Implications for GLUT5 Regulation in Renal Cell Carcinoma

        Bioinformatics Investigations Uncover the Involvement of RIPK1 in Clear Cell Renal Cell Carcinoma

        Dana-Farber Research News 12.15.2025

        This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 16 - 30.

        • by

        • December 15, 2025

        • 19 min